Adoptive Cell Therapy Across Cancer Diagnoses

Trial Profile

Adoptive Cell Therapy Across Cancer Diagnoses

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 14 Mar 2020 to 13 Mar 2020.
    • 09 Nov 2017 Planned primary completion date changed from 14 Oct 2019 to 13 Oct 2019.
    • 09 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top